Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-induced dyskinesia. The company also develops ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM); and GABAB PAM for the treatment pain, anxiety, addiction, cough, and overactive bladder. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the develop mGlu2 PAM compounds for the treatment of human health; and license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland. Show more

Location: Chemin des Mines, 9, Geneva, 1202, Switzerland | Website: https://www.addextherapeutics.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

9.918M

52 Wk Range

$6.51 - $13.27

Previous Close

$8.94

Open

$9.05

Volume

5,987

Day Range

$8.83 - $9.10

Enterprise Value

922.7M

Cash

2.825M

Avg Qtr Burn

-944.5K

Insider Ownership

0.00%

Institutional Own.

1.23%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.